New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
08:06 EDTNVIVInvivo Therapeutics receives notice of allowance from USPTO
InVivo Therapeutics Holdings Corp. announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application No. 14/177,888, titled “Methods and Compositions for the Treatment of Open and Closed Wound Spinal Cord Injuries”. The application covers InVivo’s Neuro-Spinal Scaffold, which is currently being studied in a pilot clinical trial, and its Neuro-Spinal Scaffold combined with stem cells, which is being developed for the treatment of chronic spinal cord injury. InVivo is the exclusive licensee of this intellectual property for spinal cord injury and other indications through a license with Boston Children’s Hospital and the Massachusetts Institute of Technology. A notice of allowance from the USPTO is a written notification that a patent application has cleared internal review and is pending issuance.
News For NVIV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
09:03 EDTNVIVInvivo reports reopening of enrollment in neuro-spinal scaffold trial
InVivo Therapeutics Holdings announced the reopening of subject enrollment for the company’s ongoing Investigational Device Exemption pilot study of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury. Barring significant safety issues, the final three subjects of this pilot trial will be enrolled concurrently and without mandatory safety hold between enrollment of each subject. To date, there have been no reported serious safety events related to the Neuro-Spinal Scaffold or the procedure to implant the Neuro-Spinal Scaffold with the study’s first and second subjects, and InVivo has been approved by FDA and the Data Safety Monitoring Board to move forward with the study. As specified in the study protocol, the DSMB is a committee of independent clinical research experts charged with examining the safety data accumulated during the trial. This is the company’s first clinical study of its investigational degradable polymer Neuro-Spinal Scaffold. The IDE pilot study has been approved by the FDA and is intended to capture preliminary safety and effectiveness data of the Neuro-Spinal Scaffold in five subjects with acute thoracic spinal cord injury. InVivo then expects to conduct a pivotal study to obtain FDA approval to commence commercialization under a Humanitarian Device Exemption.
March 24, 2015
08:01 EDTNVIVInvivo Therapeutics announces 1-for-4 reverse stock split
InVivo Therapeutics Holdings announced that its Board of Directors has approved a 1-for-4 reverse stock split of its issued and outstanding common stock in preparation for its planned uplisting to the NASDAQ Capital Market. The company anticipates the reverse stock split to become effective and its common stock to begin trading on a post-split basis at the open of trading on April 8, contingent upon approval from the Financial Industry Regulatory Authority. The reverse stock split is intended to fulfill InVivo’s requirements for listing to the NASDAQ Capital Market since the requirements include that a company’s common stock must maintain a minimum closing price of $3.00 for at least five trading days.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use